Study type: In vivo/preclinical · Status: Verified against declared source
Application of peripheral-blood-derived endothelial progenitor cell for treating ischemia-reperfusion injury and infarction: a preclinical study in rat models.
Journal of cardiothoracic surgery · 2013
Study scale: An accumulation of cardiovascular risk factors and the presence of coronary or peripheral atherosclerosis have been found to be associated with dysfunction and reduced numbers of EPCs [9-11].
Abstract only: Open source record
Product or molecular entity relationships
- Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Our aim was to explore the therapeutic effects of peripheral blood-derived endothelial progenitor cells (PB-EPC) in cardiac ischemia-reperfusion infarction models in rats and in in vitro culture systems.
Methods
EPCs were isolated and identified as previously described [16].
Scale or participants
An accumulation of cardiovascular risk factors and the presence of coronary or peripheral atherosclerosis have been found to be associated with dysfunction and reduced numbers of EPCs [9-11].
Key findings
Our aim was to explore the therapeutic effects of peripheral blood-derived endothelial progenitor cells (PB-EPC) in cardiac ischemia-reperfusion infarction models in rats and in in vitro culture systems.
Limitations and uncertainty
Transplantation of various types of cells have been investigated as possible treatment for cardiac dysfunction after myocardial infarction [4-6], including human umbilical vein endothelial cells [4], microspheres and fibroblasts [5], and progenitor cell populations [6].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.